The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer

Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases

(2015) Lisa D. Volk et al.   NEOPLASIA

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

(2013) A. Quintas-Cardama et al.   CLINICAL CANCER RESEARCH

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer

(2013) Changhua Zhang et al.   PLoS One

Overexpression of Forkhead Box M1 Transcription Factor (FOXM1) is a Potential Prognostic Marker and Enhances Chemoresistance for Docetaxel in Gastric Cancer

(2012) Kaoru Okada et al.   ANNALS OF SURGICAL ONCOLOGY

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

(2012) Anna-Maria Jegg et al.   BREAST CANCER RESEARCH AND TREATMENT

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

(2012) Annett Mueller et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeted Therapy for Gastric Cancer

(2012) Elizabeth C. Smyth et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

(2012) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer

(2012) Changhua Zhang et al.   JOURNAL OF SURGICAL RESEARCH

BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer

(2012) N. Awasthi et al.   MOLECULAR CANCER THERAPEUTICS

Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?

(2012) H. Wong et al.   ONCOLOGIST

Inhibitors of Phosphatidylinositol 3′-Kinases Promote Mitotic Cell Death in HeLa Cells

(2012) Heli Hou et al.   PLoS One

Update of Adjuvant Chemotherapy for Resected Gastric Cancer

(2012) Sang Cheul Oh   Journal of Gastric Cancer

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dual blockade of phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer

(2011) Rui Xu et al.   CANCER LETTERS

Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: More than just AKT inhibition

(2011) Hui Sun et al.   CANCER LETTERS

Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [ 18 F]FLT Uptake

(2011) Thorsten Fuereder et al.   CLINICAL CANCER RESEARCH

Asymmetric localisation of cytokine mRNA is essential for JAK/STAT activation during cell invasiveness

(2011) Véronique Van De Bor et al.   DEVELOPMENT

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

(2011) Robert L. Coleman et al.   GYNECOLOGIC ONCOLOGY

Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer

(2011) Jianbo Xu et al.   INTERNATIONAL JOURNAL OF CANCER

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

(2011) Niranjan Awasthi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of albumin on drug delivery — New applications on the horizon

(2011) Bakheet Elsadek et al.   JOURNAL OF CONTROLLED RELEASE

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer

(2011) Junichi Matsubara et al.   ONCOLOGY

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma

(2010) Lisa A. Kottschade et al.   CANCER

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

(2009) Narikazu Boku et al.   LANCET ONCOLOGY

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancer—An Extended Phase I MARGIT and AIO Trial

(2008) Ralf-Dieter Hofheinz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling

(2008) Niranjan Awasthi et al.   LABORATORY INVESTIGATION

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS